Kaiser Permanente halts youth gender surgeries amid federal scrutiny but keeps pushing puberty blockers
- Kaiser Permanente pauses gender-reassignment surgeries for minors under 19, citing federal regulatory changes under Trump’s executive order.
- The healthcare provider will continue offering puberty blockers and cross-sex hormones, drawing criticism for prioritizing profits over patient safety.
- Trump’s order cuts federal funding for underage medical transitions and investigates potential Medicaid fraud by gender clinics.
- Detransitioner Chloe Cole applauds the move, highlighting the irreversible harm caused by youth medicalization.
- Critics argue the gender industry exploits vulnerable children, with studies showing most outgrow gender dysphoria without intervention.
In a major victory for child welfare and medical ethics, one of the nation’s largest healthcare providers, Kaiser Permanente, has announced it will pause gender-reassignment surgeries for minors under 19, effective August 29. The decision comes in response to sweeping federal regulatory changes under President Donald Trump’s executive order cracking down on the experimental and irreversible medicalization of children struggling with gender confusion.
While this is a crucial step in protecting vulnerable youth, Kaiser’s refusal to halt all so-called “gender-affirming” interventions—including puberty blockers and cross-sex hormones—reveals the deep financial and ideological entrenchment of the
transgender medical industry.
A long-overdue pause on irreversible harm
Kaiser Permanente’s announcement cited a shifting “legal and regulatory environment” as the driving force behind its decision. “After significant deliberation and consultation with internal and external experts including our physicians, we’ve made the difficult decision to pause [surgeries] for patients under the age of 19 in our hospitals and surgical centers,” the statement read. However, the healthcare giant made clear it would continue offering other experimental treatments, declaring, “All other gender-affirming care treatment remains available.”
This partial retreat follows President Trump’s January 2025 executive order, which stripped federal funding from institutions pushing underage medical transitions and launched investigations into potential Medicaid fraud and misrepresentation by gender clinics.
The order also mandated a review of medical literature—something activists have long avoided, given the mounting evidence of harm.
Detransitioner Chloe Cole, who was subjected to irreversible surgeries as a minor before realizing the devastating consequences, celebrated the move, writing, “These incremental wins must be celebrated! We are winning! Thank you to the Trump administration for protecting kids!!!”
Profits over patients: The ugly truth behind youth transitions
While activists frame these procedures as “lifesaving,” whistleblowers and undercover investigations reveal a far darker reality. In 2022,
Vanderbilt University Medical Center’s Clinic for Transgender Health was exposed in a bombshell video where Dr. Shayne Sebold Taylor admitted, “These surgeries make a lot of money.” This profit-driven mindset has fueled an industry preying on confused children, many of whom would otherwise outgrow their gender dysphoria naturally.
Studies show that over 80% of children experiencing gender confusion eventually reconcile with their biological sex if left untreated. Yet, instead of providing therapy to address underlying mental health struggles, clinics rush to prescribe puberty blockers, cross-sex hormones, and even double mastectomies for girls as young as 13. The results? Lifelong infertility, bone density loss, and psychological trauma—all while lining the pockets of surgeons and pharmaceutical companies.
Despite this, California’s far-left Attorney General Rob Bonta has vowed to resist federal oversight, joining lawsuits to keep the gender industry’s cash flow uninterrupted. Meanwhile, nurses like Lady Rainsard of Kaiser San Francisco parrot activist talking points, claiming, “Gender-affirming care is safe and effective.” But where is the long-term safety data? Where are the follow-up studies on detransitioners like Chloe Cole, left scarred and sterilized before they could legally vote?
The fight for sanity continues
Kaiser’s decision is a step in the right direction, but the battle is far from over. The healthcare system still plans to push puberty blockers and hormones on minors—treatments with devastating, irreversible consequences. Meanwhile, institutions like Stanford Medicine and Children’s Hospital Los Angeles have also caved to federal pressure, halting surgeries while continuing other harmful interventions.
State Sen. Scott Wiener (D-San Francisco) blasted Kaiser’s move as folding under pressure, proving just how radical the opposition has become. These politicians would rather sacrifice children’s health than admit the truth: The transgender industry has been built on junk science, corporate greed, and the exploitation of vulnerable youth.
The Trump administration’s actions mark the first serious effort to hold this corrupt system accountable. Investigations into Medicaid fraud, subpoenas of
gender clinics, and the defunding of abusive practices are long overdue. But until hospitals like Kaiser stop all experimental interventions on minors, the fight must continue.
Sources for this article include:
LifeSiteNews.com
Axios.com
SFGate.com
SeattleTimes.com